Bayer Aktiengesellschaft

Qiagen Gmbh

Chemotherapeutisches Forschunginstitut Georg-Speyer-Haus

Chemotherapeutisches Forschungsinstitut

Chemotherapeutisches Forschunginstitut Georg Speyer-Haus Zu Frankfurt

Helga Rubsamen-Waigmann

Hagen Von Briesen

Ursula Dietrich

Herbert Kuhnel

Michalina Adamski

Axel Kretschmer

Karsten Henco

Burkhard Mielke

Udo Stropp

Andreas Immelmann

Manuel Grez

Lothar Biesert

Wolfgang Springer

Horst-Peter Antonicek

Jorg Baumgarten

Antonius Lobberding

Hary Suhartono

Mark-Michael Struck

Antonius Loebberding

Axel C Heitmann

Haryadi Suhartono

Thomas-Peter Hausner

Three new HIV-1 isolates HIV-1 D747(ECACC V92082718), HIV-1 D757(ECACC V92082719) and HIV-1 D760(ECACC V92082720) are disclosed, which represent a further independent subtype of the HIV-1 family and have been recovered from Indian patients which at the time when the virus was isolated showed no typical AIDS symptoms. Also disclosed are vaccines against HIV-1 infections by this subtype and a process for producing the same, as well as the use of the HIV-1 infection, as well as for differential diagnosis.

HIV-1 virus isolates of a subtype and its differential diagnostics, a vaccine against HIV-1 virus infections of this subtype and method of producing same, use of the HIV-1 virus isolates

HIV-1 virus isolates of a subtype and its differential diagnostics

Vaccine for protection against HIV infections, therapeutic agents for treatment subsequent to HIV infections, process for their preparation and their use; procedure for differentiation between HIV-2.sub.ALT type infections and HIV-2 infections defined by the prototype HIV-2.sub.ROD. Subject matter of the present invention are the virus HIV-2.sub.D205 as well as HIV-2 variants distinguishing from the HIV-2 prototypes of the type HIV-2.sub.ROD in that nucleotide sequence homology is less than 77%. Further, proteins and nucleic acids of HIV-2.sub.D205 and its variants for utilization as vaccines for protection against HIV infections, for geno- or immunotherapy, for establishing an animal model, and for differential diagnostics are part of this invention. Furthermore, the processes for preparing these vaccines, immunotherapeutic and diagnostic agents as well as their use are part of this invention.

Vaccine for protection against HIV infections, process for preparing

HIV-2 virus variants, namely virus HIV D194 and virus HIV D205, which can be cloned from the corresponding virus isolate HIV D194 (ECACC V 87122303) or from the infected cell line HUT 194 (ECACC V 87122306) or from the virus isolate HIV D205 (ECACC V 87122304), respectively, and their RNA or RNA-fragments and DNA and DNA-fragments derived therefrom and/or proteins and the use thereof for diagnostics and therapy.

HIV-2 virus variants

The present invention relates to the targeted blocking of the genetic information of the viral messenger ribonucleic acid (mRNA) for virus replication (e.g. of HIV) in transfected, haematopoietic cells with particularly suitable expression systems, which express a complementary 'antisense RNA'.

HIV antisense expression vectors

Novel oligophosphates with an antiviral action of the formula ##STR1## in which n is 3-50,

Oligophosphates with an antiviral action

Growing community of inventors

Bad Soden, Germany

Helga Rubsamen-Waigmann